Low-grade, Low-stage Endometrioid Endometrial Adenocarcinoma

Quick CM, Charles M Quick, Taymaa May, May T, Neil S Horowitz, Horowitz NS, Nucci MR, Marisa R Nucci
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2012 · vol. 31(4) , pp. 337–343 · doi:10.1097/pgp.0b013e31823ff422 · PMID:22653347 · W2071439557
article OA: closed CC0 ⤵ 5 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-07, 2026-07-17 ⓘ

This study analyzed myometrial invasion patterns in low-grade endometrial adenocarcinoma, finding the infiltrative gland pattern was associated with higher stage, lymphovascular invasion, and recurrence.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Patients with low-stage, low-grade endometrial adenocarcinomas have a favorable prognosis; however, a subset has a risk of recurrence and death. We were interested in evaluating patterns of myometrial invasion and correlating them with clinical outcome to potentially identify patients at increased risk. A total of 324 cases of low-stage Grade 1 endometrial adenocarcinoma were reviewed to identify those with myoinvasion. The myoinvasive cases were classified on the basis of the pattern of invasion: infiltrating glands, microcystic elongated and fragmented (MELF; a distinctive histologic variant of the infiltrative gland pattern), broad front, adenomyosis like, and adenoma malignum. Depth of invasion and lymphovascular invasion were recorded, and a clinical follow-up of at least 2 y was obtained, as most recurrences occur in this time frame. Ninety-eight of 324 (30%) cases were invasive; 75 had >2 y of follow-up, with an average length of follow-up of >7 y (range, 24-154 mo; mean 87 mo). All patients had a hysterectomy and bilateral salpingo-oophorectomy; 39 (52%) also underwent a lymphadenectomy. Twenty-seven (36%) were superficially invasive (50%. Six (8%) cases exhibited cervical stromal invasion (Stage II); the rest were Stage I (65 IA, 4 IB). The invasive patterns consisted of infiltrative glands (48; 65%), a broad front (16; 21%), MELF (5; 7%), adenomyosis like (5; 7%), and adenoma malignum like (1, 1%). There were 65 Stage 1A cases and, of these, the myoinvasive pattern was as follows: 41 infiltrating glands, 15 broad front, 5 MELF, and 4 adenomyosis like. There were 4 Stage IB cases, of which 2 had infiltrating glands, 1 had adenoma malignum, and 1 displayed adenomyosis-like invasion. Six (8%) cases had cervical stromal invasion (Stage II), of which 5 had an infiltrative pattern of growth and 1 displayed a broad front. Lymphovascular invasion was noted in 6 cases (8%), all of which had infiltrative glands. The majority of Grade 1 endometrioid endometrial adenocarcinomas do not invade the myometrium. In cases with invasion, the infiltrative gland pattern was associated with higher stage, (3/4 Stage IB, 5/6 Stage II), lymphovascular invasion (4/6 cases), and recurrence (2/75 cases), suggesting that this growth pattern may be associated with tumors having other histologic features typically associated with more aggressive behavior.

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Carcinoma, Endometrioid Endometrial Neoplasms Myometrium Adult Aged Aged, 80 and over Carcinoma, Endometrioid Carcinoma, Endometrioid Endometrial Neoplasms Endometrial Neoplasms Female Histocytochemistry Humans Middle Aged Myometrium Neoplasm Recurrence, Local Neoplasm Recurrence, Local Prognosis Retrospective Studies

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (17)

Cited by (7)

Source provenance

europepmc
last seen: 2026-07-27T06:15:28.040536+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:16:11.197438+00:00
unpaywall
last seen: 2026-07-27T06:55:32.580041+00:00
License: CC0 · commercial use OK